Bausch + Lomb Corporation reported total revenue of $1.375 billion for the third quarter of 2026, representing a 7% increase compared to the same period in 2025. On a constant currency basis, revenue grew by approximately 8%. The company reported GAAP net income attributable to Bausch + Lomb of $32 million for the quarter, compared to a loss of $28 million in the prior year.
Revenue growth was driven by all three business segments. The Vision Care segment generated $774 million, up 5% year-over-year, while the Surgical segment reported $234 million, up 9%. The Pharmaceuticals segment saw the strongest growth at $367 million, an increase of 11%.
Key product highlights included MIEBO revenue growing 42% to $119 million, LUMIFY revenue growing 35%, and the Daily SiHy contact lens portfolio growing 24%. The premium IOL portfolio grew approximately 70%.
On October 28, 2026, the company updated its full-year 2026 guidance. Revenue is now expected to be between $5.450 billion and $5.550 billion, with constant currency growth projected between 6.1% and 8.0%. Adjusted EBITDA excluding acquired IPR&D is expected to range from $1.090 billion to $1.140 billion.
